Tests ABBV-142 in adults with idiopathic pulmonary fibrosis
Tests ABBV-142 or a placebo in adults with scarring lung disease.
Plain-language title generated from the registry record
Registry title: Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Key facts
- Where
- Ann Arbor, Birmingham, Champaign, Detroit, Dothan, Falls Church, Hannibal, Kissimmee, Philadelphia, and Richmond, United StatesSee the 10 sites
- Phase
- Phase 2
Where in United States
- University of Michigan Health System - Ann Arbor /ID# 279994Ann Arbor, United StatesTaking people
- The University of Alabama at Birmingham /ID# 277613Birmingham, United StatesTaking people
- Christie Clinic on University /ID# 277871Champaign, United StatesTaking people
- Henry Ford Hospital /ID# 277843Detroit, United StatesTaking people
- Sec Clinical Research - East - Dothan - Graceland /ID# 278328Dothan, United StatesTaking people
- Inova Fairfax Hospital /ID# 278469Falls Church, United StatesTaking people
- Hannibal Regional Hospital /ID# 277984Hannibal, United StatesTaking people
- Clinical Research Specialists - Kissimmee /ID# 279184Kissimmee, United StatesTaking people
- Jefferson Health Honickman Center /ID# 279127Philadelphia, United StatesTaking people
- Virginia Commonwealth University Medical Center /ID# 277992Richmond, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT07230288EU 2024-518013-25-00
- Record updated
- 3 September 2026
- Original description
Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time. The main goals of the study are to evaluate the safety, tolerability (the degree to which the adverse symptoms can be handled by the patients during the study) and efficacy (how well study treatment works) of the study treatments, including ABBV-142 in Substudy 1 (SS1).Read full original descriptionShow less
A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time. The main goals of the study are to evaluate the safety, tolerability (the degree to which the adverse symptoms can be handled by the patients during the study) and efficacy (how well study treatment works) of the study treatments, including ABBV-142 in Substudy 1 (SS1).
ABBV-142 is an investigational drug being developed for the treatment of IPF. In SS1, participants will be randomly assigned to one of the 2 groups to receive either ABBV-142 or a matching placebo. This study is "double-blind", meaning that neither the participants nor the study doctors know who is given which study treatment. Approximately 165 adult participants with IPF will be enrolled in approximately 125 sites across the world.
Participants will receive ABBV-142 or matching placebo for 52 weeks during the double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks in open-label treatment period. All participants will be followed for 120 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Inclusion: Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verification of usual interstitial pneumonia(UIP) or probable UIP.
Exclusion: History of stroke within 6 months prior to screening; History of any malignancy up to 5 years prior screening visit, except for successfully treated nonmelanoma skin cancer or localized carcinoma in situ of the cervix; In the opinion of the investigator, other clinically significant pulmonary abnormalities.